BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 27992936)

  • 1. Role of Isradipine Loaded Solid Lipid Nanoparticles on the Pharmacodynamic Effect in Rats.
    Thirupathi G; Swetha E; Narendar D
    Drug Res (Stuttg); 2017 Mar; 67(3):163-169. PubMed ID: 27992936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved anti-hyperlipidemic activity of Rosuvastatin Calcium via lipid nanoparticles: Pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Eur J Pharm Biopharm; 2017 Jan; 110():47-57. PubMed ID: 27810472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design.
    Dudhipala N; Veerabrahma K
    Drug Dev Ind Pharm; 2015; 41(12):1968-77. PubMed ID: 25830370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery.
    Rawat MK; Jain A; Mishra A; Muthu MS; Singh S
    Ther Deliv; 2010 Jul; 1(1):63-73. PubMed ID: 22816120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Domperidone Solid Lipid Nanoparticles: In Vitro and In Vivo Characterization.
    Shazly GA; Alshehri S; Ibrahim MA; Tawfeek HM; Razik JA; Hassan YA; Shakeel F
    AAPS PharmSciTech; 2018 May; 19(4):1712-1719. PubMed ID: 29532427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles.
    Vivek K; Reddy H; Murthy RS
    AAPS PharmSciTech; 2007 Oct; 8(4):E83. PubMed ID: 18181544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
    Das S; Ng WK; Tan RB
    Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics.
    Ji P; Yu T; Liu Y; Jiang J; Xu J; Zhao Y; Hao Y; Qiu Y; Zhao W; Wu C
    Drug Des Devel Ther; 2016; 10():911-25. PubMed ID: 27041995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: optimization, in vitro and in vivo evaluation.
    Dudhipala N; Janga KY
    Drug Dev Ind Pharm; 2017 Jul; 43(7):1205-1214. PubMed ID: 28274147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation, characterization, pharmacokinetics and tissue distribution of solid lipid nanoparticles loaded with tetrandrine.
    Li S; Ji Z; Zou M; Nie X; Shi Y; Cheng G
    AAPS PharmSciTech; 2011 Sep; 12(3):1011-8. PubMed ID: 21811889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.
    Dudhipala N; Janga KY; Gorre T
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):616-625. PubMed ID: 29688077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine a loaded solid lipid nanoparticles: optimization of formulation, process variable and characterization.
    Varia JK; Dodiya SS; Sawant KK
    Curr Drug Deliv; 2008 Jan; 5(1):64-9. PubMed ID: 18220553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization.
    Liu J; Gong T; Wang C; Zhong Z; Zhang Z
    Int J Pharm; 2007 Aug; 340(1-2):153-62. PubMed ID: 17428627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells.
    Vieira AC; Chaves LL; Pinheiro M; Ferreira D; Sarmento B; Reis S
    Int J Nanomedicine; 2016; 11():2601-17. PubMed ID: 27354792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique.
    Negi JS; Chattopadhyay P; Sharma AK; Ram V
    Eur J Pharm Sci; 2013 Jan; 48(1-2):231-9. PubMed ID: 23153618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Oral Absorption of All-trans Retinoic Acid upon Encapsulation in Solid Lipid Nanoparticles.
    Kumar M; Sharma G; Singla D; Singh S; Kakkar V; Gulati JS; Kaur IP
    Pharm Nanotechnol; 2020; 8(6):495-510. PubMed ID: 33115399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of liquid-to-solid lipid ratio on characterizations of flurbiprofen-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for transdermal administration.
    Song A; Zhang X; Li Y; Mao X; Han F
    Drug Dev Ind Pharm; 2016 Aug; 42(8):1308-14. PubMed ID: 26707734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics.
    Kumar VV; Chandrasekar D; Ramakrishna S; Kishan V; Rao YM; Diwan PV
    Int J Pharm; 2007 Apr; 335(1-2):167-175. PubMed ID: 17161566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system.
    Chalikwar SS; Belgamwar VS; Talele VR; Surana SJ; Patil MU
    Colloids Surf B Biointerfaces; 2012 Sep; 97():109-16. PubMed ID: 22609590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.